Email: cspc@cspc.cn
Media
News Center
Apr. 26
2024
VOLUNTARY ANNOUNCEMENT HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr. 18
CSPC Ranks Among Top 15 Value-leading Chinese Listed Innovative Drug Companies
Mar. 29
Results of a Phase III Clinical Study on Batoclimab of CSPC Published in JAMA Sub-journal
Mar. 25
VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL
VOLUNTARY ANNOUNCEMENT SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL
Mar. 21
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
